Table 3.
Association between clinical factors and the number of PD-L1-expressing peripheral blood mononuclear cell (PBMC) subsets
| Variable | All, n (%) | PD-L1+CD3+ Tcells (%) |
p value | PD-L1+CD8+ Tcells (%) |
p value | PD-L1+CD20+ Bcells (%) |
p value | PD-L1+CD14+ monocytes (%) |
p value | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sex | Male | 15 (71.4) | 1.01 | 0.549 | 0.39 | 0.213 | 0.19 | 0.847 | 3.99 | 0.863 |
| Female | 6 (28.6) | 0.78 | 0.31 | 0.46 | 3.57 | |||||
| Age | < 70 Years | 12 (57.1) | 1.16 | 0.751 | 0.42 | 0.541 | 0.29 | 0.556 | 6.10 | 0.259 |
| ≥ 70 Years | 9 (42.9) | 0.82 | 0.39 | 0.32 | 3.11 | |||||
| Cancer type | NSCLC | 11 (52.4) | 1.01 | 0.63 | 0.40 | 0.449 | 0.24 | 0.471 | 3.99 | 0.179 |
| Other | 10 (47.6) | 0.78 | 0.25 | 0.34 | 12.21 | |||||
| Clinical stage | III | 6 (28.6) | 0.82 | 0.603 | 0.28 | 0.649 | 0.31 | 0.394 | 3.62 | 0.319 |
| IV | 15 (71.4) | 1.63 | 0.75 | 0.23 | 15.29 | |||||
| Observed Response | PD | 10 (47.6) | 1.25 | 0.150 | 0.63 | 0.226 | 0.31 | 0.396 | 4.18 | 0.083 |
| PR and SD | 11 (52.4) | 0.78 | 0.275 | 0.24 | 3.56 |
Patients were divided on the basis of the median percentage of indicated subsets
NSCLC non-small cell lung cancer; PD progressive disease; SD stable Disease